Literature DB >> 28623872

Uptake in sympathetic ganglia on 68 Ga-PSMA-HBED PET/CT: A potential pitfall in scan interpretation.

Gowri L Kanthan1,2, Edward Hsiao1, Dzung Vu3, Geoffrey Paul Schembri1.   

Abstract

INTRODUCTION: The aim of this study was to assess the frequency of PSMA-HBED uptake in coeliac and stellate ganglia in patients presenting for PSMA-HBED PET/CT scan.
METHODS: Prostate-specific membrane antigen-HBED PET/CT scans of 100 consecutive patients were analysed. Coeliac and stellate ganglia were identified by their anatomical location. PSMA-HBED uptake in these ganglia was recorded as either present or absent. If present, the SUVmax value for each ganglion was measured and compared to SUVmax of mediastinal blood pool.
RESULTS: Of the 100 patients, 45 had PSMA-HBED uptake in the right coeliac ganglion and 81 had PSMA-HBED uptake in the left coeliac ganglion. The mean SUVmax for the right coeliac ganglion was 2.6 (range 1.2-4.0) and for the left, 2.7 (range 1.2-6.5). An SUVmax 1.5 times greater than that of mediastinal blood pool activity was found in 25 of right and 47 of left coeliac ganglia. Stellate ganglion uptake of PSMA-HBED was identified in 54 of right and 74 of left stellate ganglia. The mean SUVmax for the right and left stellate ganglia were 2.2 (range 1.6-3.6) and 2.4 (range 1.4-4.2) respectively. An SUVmax 1.5 times greater than that of mediastinal blood pool activity was found in 12 of right and 32 of left coeliac ganglia.
CONCLUSION: Uptake in coeliac and stellate ganglia is a frequent finding on PSMA-HBED PET/CT imaging. Often this uptake can be sufficiently high to cause potential diagnostic confusion. It is important to be aware of this physiologic uptake to avoid incorrect diagnosis of metastatic prostate carcinoma.
© 2017 The Royal Australian and New Zealand College of Radiologists.

Entities:  

Keywords:  PSMA PET/CT scan; prostate carcinoma; sympathetic ganglia

Mesh:

Substances:

Year:  2017        PMID: 28623872     DOI: 10.1111/1754-9485.12622

Source DB:  PubMed          Journal:  J Med Imaging Radiat Oncol        ISSN: 1754-9477            Impact factor:   1.735


  10 in total

Review 1.  Targeting PSMA by radioligands in non-prostate disease-current status and future perspectives.

Authors:  Philipp Backhaus; Benjamin Noto; Nemanja Avramovic; Lena Sophie Grubert; Sebastian Huss; Martin Bögemann; Lars Stegger; Matthias Weckesser; Michael Schäfers; Kambiz Rahbar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-01-15       Impact factor: 9.236

2.  Digital versus analogue PET in [68Ga]Ga-PSMA-11 PET/CT for recurrent prostate cancer: a matched-pair comparison.

Authors:  Ian Alberts; George Prenosil; Christos Sachpekidis; Thilo Weitzel; Kuangyu Shi; Axel Rominger; Ali Afshar-Oromieh
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-12-02       Impact factor: 9.236

3.  The role of additional late PSMA-ligand PET/CT in the differentiation between lymph node metastases and ganglia.

Authors:  Ian Alberts; Christos Sachpekidis; Lotte Dijkstra; George Prenosil; Eleni Gourni; Silvan Boxler; Tobias Gross; George Thalmann; Kambiz Rahbar; Axel Rominger; Ali Afshar-Oromieh
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-12-21       Impact factor: 9.236

4.  Dynamic patterns of [68Ga]Ga-PSMA-11 uptake in recurrent prostate cancer lesions.

Authors:  Ian Alberts; Christos Sachpekidis; Eleni Gourni; Silvan Boxler; Tobias Gross; George Thalmann; Kambiz Rahbar; Axel Rominger; Ali Afshar-Oromieh
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-10-18       Impact factor: 9.236

5.  Patterns of uptake of prostate-specific membrane antigen (PSMA)-targeted 18F-DCFPyL in peripheral ganglia.

Authors:  Rudolf A Werner; Sara Sheikhbahaei; Krystyna M Jones; Mehrbod S Javadi; Lilja B Solnes; Ashley E Ross; Mohamad E Allaf; Kenneth J Pienta; Constantin Lapa; Andreas K Buck; Takahiro Higuchi; Martin G Pomper; Michael A Gorin; Steven P Rowe
Journal:  Ann Nucl Med       Date:  2017-08-22       Impact factor: 2.668

6.  Synthesis and Preclinical Characterization of the PSMA-Targeted Hybrid Tracer PSMA-I&F for Nuclear and Fluorescence Imaging of Prostate Cancer.

Authors:  Margret Schottelius; Alexander Wurzer; Katharina Wissmiller; Roswitha Beck; Maximilian Koch; Dimitrios Gorpas; Johannes Notni; Tessa Buckle; Matthias N van Oosterom; Katja Steiger; Vasilis Ntziachristos; Markus Schwaiger; Fijs W B van Leeuwen; Hans-Jürgen Wester
Journal:  J Nucl Med       Date:  2018-09-20       Impact factor: 10.057

7.  Intra-patient comparison of physiologic 68Ga-PSMA-11 and 18F-DCFPyL PET/CT uptake in ganglia in prostate cancer patients: a pictorial essay.

Authors:  Medhat M Osman; Amir Iravani; Michael S Hofman; Rodney J Hicks
Journal:  Cancer Imaging       Date:  2021-04-16       Impact factor: 3.909

8.  Celiac ganglia: can they be misinterpreted on multimodal 68Ga-PSMA-11 PET/MR?

Authors:  Ewa J Bialek; Bogdan Malkowski
Journal:  Nucl Med Commun       Date:  2019-02       Impact factor: 1.690

9.  The "question-mark" MR anatomy of the cervico-thoracic ganglia complex: can it help to avoid mistaking it for a malignant lesion on 68Ga-PSMA-11 PET/MR?

Authors:  Ewa J Bialek; Bogdan Malkowski
Journal:  Radiol Oncol       Date:  2019-10-25       Impact factor: 2.991

10.  The influence of digital PET/CT on diagnostic certainty and interrater reliability in [68Ga]Ga-PSMA-11 PET/CT for recurrent prostate cancer.

Authors:  Ian Alberts; Jan-Niklas Hünermund; Christos Sachpekidis; Clemens Mingels; Viktor Fech; Karl Peter Bohn; Axel Rominger; Ali Afshar-Oromieh
Journal:  Eur Radiol       Date:  2021-04-15       Impact factor: 5.315

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.